Abstract: The invention provides novel compounds, in particular peptide and peptide analogs, which exhibit functionalities useful for treating a variety of diseases and conditions, particularly diseases and conditions relating to diabetes. The compounds of the invention are also useful for treating impaired pancreatic function, treating metabolic diseases, ex vivo islet induction, expansion and proliferation for transplantation, increasing the survival of transplanted islets in vivo, promoting neuroprotection or nerve regeneration, promoting liver regeneration, and inhibiting inflammation.
Abstract: The present disclosure provides a high-activity memory-improving derivative peptide and use thereof in preparation of memory-improving medicaments, health care products or foods, and belongs to the field of biotechnology. According to the present disclosure, proline 3 (Pro3) of a pine nut high-activity memory-improving peptide, WYPGK, is completely substituted with common amino acids to obtain 19 derivative peptides, and the derivative peptides are subjected to molecular docking with mitochondrial deacetylase sirtuin 3 and are screened by binding energy to obtain derivative peptides WYEGK, WYKGK, WYSGK, and WYFGK; solid-phase chemical synthesis is conducted by a peptide synthesizer; the derivative peptides are purified by reversed phase high performance liquid chromatography (RP-HPLC) and prepared by electrospray ionization mass spectrometry (ESI-MS). Morris water maze for scopolamine-induced memory impairment model mice demonstrates that the derivative peptides have high memory-improving activity.
Type:
Grant
Filed:
September 29, 2022
Date of Patent:
October 10, 2023
Assignee:
JILIN AGRICULTURAL UNIVERSITY
Inventors:
Weihong Min, Hongyan Lu, Chunlei Liu, Ji Wang, Li Fang
Abstract: The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs. Methods of using the lysin-AMP polypeptide constructs, isolated lysin polypeptides and pharmaceutical compositions are also herein provided. In addition, isolated polynucleotides encoding the lysin-AMP polypeptide constructs and isolated lysin polypeptides are disclosed herein.
Abstract: Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
September 12, 2023
Assignee:
Alpine Immune Sciences, Inc.
Inventors:
Lawrence Evans, Joseph L. Kuijper, Ryan Swanson
Abstract: The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
September 12, 2023
Assignee:
Ra Pharmaceuticals, Inc.
Inventors:
Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
Type:
Grant
Filed:
February 3, 2021
Date of Patent:
September 5, 2023
Assignee:
MEDIKINE, INC.
Inventors:
William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
Type:
Grant
Filed:
November 18, 2022
Date of Patent:
September 5, 2023
Assignee:
Viking Therapeutics, Inc.
Inventors:
Brian Lian, Geoffrey E. Barker, Maureen Barnes, Kader Yagiz, Erland Stevens
Abstract: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more modified HMG-box 1 domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
September 5, 2023
Assignee:
Research Institute at Nationwide Children's Hospital
Inventors:
Steven David Goodman, Lauren O. Bakaletz
Abstract: Provided herein are synthetic peptides developed from slug and insect neuropeptides. Peptides described can be used to repel, control or deter slugs, including the gray garden slug (Deroceras reticulatum), from feeding on agricultural and horticultural plants. The peptides can be combined with bait materials, or applied directly to plants or areas, or produced by genetically modified plants.
Type:
Grant
Filed:
August 25, 2020
Date of Patent:
August 15, 2023
Assignees:
The United States of America, as represented by The Secretary Agriculture, Oregon State University
Inventors:
Man Y. Choi, Ruth C. Martin, Seungjoon Ahn, Rory McDonnell, Sujaya Rao
Abstract: Disclosed are hypersensitive-response eliciting peptides and non-hypersensitive response eliciting peptides that induce active plant responses, and that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.
Type:
Grant
Filed:
August 12, 2021
Date of Patent:
August 15, 2023
Assignee:
Ra Pharmaceuticals, Inc.
Inventors:
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
Abstract: In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing Streptococcus mutans. In certain embodiments the dental strip additionally comprises a release liner.
Type:
Grant
Filed:
April 12, 2018
Date of Patent:
July 25, 2023
Assignee:
C3 Jian, LLC
Inventors:
Evan Schauer, Miroslav Baudys, Brian C. Varnum, Duane Morris, Christopher W. Kaplan, Randal H. Eckert
Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
July 4, 2023
Assignee:
ELASMOGEN LIMITED
Inventors:
Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
Abstract: The present invention relates to variants of the general amyloid interaction motif (GAIM) of bacteriophage gene 3 protein (g3p) and fusion proteins thereof. The GAIM variants and fusion proteins of the invention are partially or fully deimmunized and demonstrate superior binding and specificity to a diverse array of amyloid proteins, and exhibit enhanced amyloid remodeling and inhibition of amyloid aggregation. The present invention further relates to nucleic acids, vectors, host cells, and methods of making the GAIM variants and fusion proteins thereof. The present invention also relates to pharmaceutical compositions and methods of increasing bacteriophage infectivity, methods of detecting amyloid aggregates, and methods of diagnosing and/or treating a disease associated with misfolded and/or aggregated amyloid protein.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
July 4, 2023
Assignee:
Amyl Therapeutics SRL
Inventors:
Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher
Abstract: Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample.
Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
June 13, 2023
Inventors:
Ugur Sahin, Bonny Gaby Lui, Nadja Salomon, Joycelyn Wüstehube-Lausch, Matin Daneschdar, Hans-Ulrich Schmoldt, Markus Fiedler